<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC6925545/results/search/drugs/results.xml">
  <result pre="MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with" exact="rituximab" post="in allo-HCT children was 19.3%. In 30.8% cases of"/>
  <result pre="which did not prevent development of EBV-DNA-emia with need of" exact="rituximab" post="treatment in 81.5% cases. In 47.7% of these cases,"/>
  <result pre="(GCV) can reduce EBV replication, but neither ganciclovir/foscarnet (FCV) nor" exact="cidofovir" post="(CDV) therapy/prophylaxis have any impact on development of EBV-PTLD,"/>
  <result pre="(81.8%) cases, a significant EBV-DNA-emia has occurred and treatment with" exact="rituximab" post="was required. In 44/54 (81.5%) of these cases viral"/>
  <result pre="were treated with antiviral drugs, including: CDV (n=18), GCV (n=17)," exact="aciclovir" post="(ACV) (n=1), oseltamivir (n=1) or drug combinations (FCV+GCV, n=5;"/>
  <result pre="antiviral drugs, including: CDV (n=18), GCV (n=17), aciclovir (ACV) (n=1)," exact="oseltamivir" post="(n=1) or drug combinations (FCV+GCV, n=5; FCV+CDV, n=2; GCV+CDV,"/>
  <result pre="FCV therapies, 1/12 (8.3%) ACV therapies and 1/13 (7.7%) of" exact="oseltamivir" post="therapies. Discussion The primary causes of morbidity and non-relapse"/>
  <result pre="risk of clinically significant CMV infection.18 We have shown that" exact="ganciclovir" post="and foscarnet were the most frequently used drugs in"/>
  <result pre="disease is a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir," exact="leflunomide" post="or artesunate can be considered in patients resistant or"/>
  <result pre="a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir, leflunomide or" exact="artesunate" post="can be considered in patients resistant or refractory to"/>
  <result pre="severity, and the selection of antibiotic resistance.19 In our study" exact="cidofovir" post="was the most frequently used drug in the treatment"/>
  <result pre="with available antiviral drugs is currently not recommended and intravenous" exact="cidofovir" post="is currently regarded as a standard of care in"/>
  <result pre="were acquired during hospitalization.17 In the case of CARV infections," exact="ribavirin" post="and intravenous immunoglobulin are recommended in hMPV, HPIV and"/>
  <result pre="from the respiratory tract, especially broncho-alveolar lavage.23 Neuraminidase inhibitors (oral" exact="oseltamivir" post="or inhalation of zanamivir) are currently the most effective"/>
  <result pre="RV- and NoV-related gastroenterocolitis is available; however, oral immunoglobulins and" exact="nitazoxanide" post="were used in some studies.24,27 In immunocompetent individuals primary"/>
  <result pre="cases in auto-HCT setting. In 80.3% (143/175) of EBV reactivations" exact="rituximab" post="was used and 93.3% of patients survived this infection."/>
  <result pre="prevent the development of significant EBV-DNA-emia with the need of" exact="rituximab" post="treatment. This is clinically proven evidence that antiviral drugs"/>
  <result pre="immunoglobulins also have no impact in PTLD. Neither ganciclovir/foscarnet nor" exact="cidofovir" post="therapy/prophylaxis have any impact on the development of EBV-PTLD,"/>
  <result pre="PTLD.8 The following pre-emptive therapies are recommended after high-risk allo-HCT:" exact="rituximab" post="(375 mg/m2/weekly), reduction of immunosuppressive therapy (if possible), donor"/>
  <result pre="MSD. The incidence of EBV infection requiring pre-emptive treatment with" exact="rituximab" post="in allo-HSCT children was 19.3%. In 30.8% of cases"/>
  <result pre="not prevent development of significant EBV-DNA-emia with the need of" exact="rituximab" post="treatment in 81.5% of cases. This is clinically proven"/>
  <result pre="allogeneic hematopoietic cell transplant recipients: clinical course and experience using" exact="nitazoxanide" post="and enterally administered immunoglobulins. Pediatr Infect Dis J. 2018;37(2):176â€“181."/>
  <result pre="2013;6:94. doi:10.1186/1756-8722-6-9424341630 29.CzyzewskiK, StyczynskiJ, KrenskaA, et al. Intrathecal therapy with" exact="rituximab" post="in central nervous system involvement of post-transplant lymphoproliferative disorder."/>
 </snippets>
</snippetsTree>
